Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,670 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia.
Alvarez-Larrán A, Senín A, Fernández-Rodríguez C, Pereira A, Arellano-Rodrigo E, Gómez M, Ferrer-Marin F, Martínez-López J, Camacho L, Colomer D, Angona A, Navarro B, Cervantes F, Besses C, Bellosillo B, Hernández-Boluda JC. Alvarez-Larrán A, et al. Among authors: pereira a. Br J Haematol. 2017 Sep;178(5):764-771. doi: 10.1111/bjh.14762. Epub 2017 May 23. Br J Haematol. 2017. PMID: 28542718 Free article.
Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis.
Martínez-Trillos A, Maffioli M, Colomer D, Alvarez-Larrán A, Pereira A, Angona A, Bellosillo B, Cervantes F. Martínez-Trillos A, et al. Among authors: pereira a. Ann Hematol. 2014 May;93(5):797-802. doi: 10.1007/s00277-013-1989-5. Epub 2013 Dec 15. Ann Hematol. 2014. PMID: 24337516
JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events.
Alvarez-Larrán A, Bellosillo B, Pereira A, Kerguelen A, Hernández-Boluda JC, Martínez-Avilés L, Fernández-Rodríguez C, Gómez M, Lombardía L, Angona A, Ancochea A, Senín A, Longarón R, Navarro B, Collado M, Besses C. Alvarez-Larrán A, et al. Among authors: pereira a. Am J Hematol. 2014 May;89(5):517-23. doi: 10.1002/ajh.23676. Epub 2014 Feb 21. Am J Hematol. 2014. PMID: 24458835 Free article.
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.
Alvarez-Larrán A, Pereira A, Guglielmelli P, Hernández-Boluda JC, Arellano-Rodrigo E, Ferrer-Marín F, Samah A, Griesshammer M, Kerguelen A, Andreasson B, Burgaleta C, Schwarz J, García-Gutiérrez V, Ayala R, Barba P, Gómez-Casares MT, Paoli C, Drexler B, Zweegman S, McMullin MF, Samuelsson J, Harrison C, Cervantes F, Vannucchi AM, Besses C. Alvarez-Larrán A, et al. Among authors: pereira a. Haematologica. 2016 Aug;101(8):926-31. doi: 10.3324/haematol.2016.146654. Epub 2016 May 12. Haematologica. 2016. PMID: 27175028 Free PMC article.
Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis.
Alvarez-Larrán A, Pereira A, Magaz M, Hernández-Boluda JC, Garrote M, Cuevas B, Ferrer-Marín F, Gómez-Casares MT, García-Gutiérrez V, Mata-Vázquez MI, Turon F, Hernandez-Gea V, Arellano-Rodrigo E, Cervantes F, García-Pagán JC; GEMFIN and REHEVASC groups. Alvarez-Larrán A, et al. Among authors: pereira a. Ann Hematol. 2020 Apr;99(4):791-798. doi: 10.1007/s00277-020-03965-z. Epub 2020 Feb 22. Ann Hematol. 2020. PMID: 32086587
Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia.
Alvarez-Larrán A, Cervantes F, Pereira A, Arellano-Rodrigo E, Pérez-Andreu V, Hernández-Boluda JC, Ayats R, Salvador C, Muntañola A, Bellosillo B, Vicente V, Hernández-Nieto L, Burgaleta C, Xicoy B, Besses C. Alvarez-Larrán A, et al. Among authors: pereira a. Blood. 2010 Aug 26;116(8):1205-10; quiz 1387. doi: 10.1182/blood-2010-01-263319. Epub 2010 May 27. Blood. 2010. PMID: 20508163 Free article.
6,670 results